Correspondence to: Dieter Maurer, Department of Dermatology/CeMM, University of Vienna Medical School, Waehringer Guertel 18-20, A-1090 Vienna, Austria. Tel:43-1-40400-7769 Fax:43-1-4031-900 E-mail:dieter.maurer{at}akh-wien.ac.at.
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Endo/lysosomal proteases control two key events in antigen (Ag) presentation: the degradation of protein Ag and the generation of peptide-receptive major histocompatibility complex (MHC) class II molecules. Here we show that the proinflammatory cytokines tumor necrosis factor and interleukin (IL)-1ß rapidly increase the activity of cathepsin (cat) S and catB in human dendritic cells (DCs). As a consequence, a wave of MHC class II sodium dodecyl sulfate stable dimer formation ensues in a catS-dependent fashion. In contrast, the antiinflammatory cytokine IL-10 renders DCs incapable of upregulating catS and catB activity and in fact, attenuates the level of both enzymes. Suppressed catS and catB activity delays MHC class II sodium dodecyl sulfate stable dimer formation and impairs Ag degradation. In DCs exposed to tetanus toxoid, IL-10 accordingly reduces the number of MHC class IIpeptide complexes accessible to tetanus toxoidspecific T cell receptors, as analyzed by measuring T cell receptor downregulation in Ag-specific T cell clones. Thus, the control of protease activity by pro- and antiinflammatory cytokines is an essential feature of the Ag presentation properties of DCs.
Key Words: antigen-presenting cell, cathepsin, class II maturation, antigen degradation, TCR
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
During their transition from an immature to a mature state, dendritic cells (DCs)1 acquire the unique ability to stimulate immunologically naive T cells. Maturation of DCs is a process initiated by cellular activation and is manifested in cells treated with proinflammatory cytokines (1) (2) (3). Upon activation, DCs lose their ability to take up external Ags but begin to export peptide-loaded MHC products to the cell surface. Within T cell areas of lymphoid organs, fully mature DCs abundantly display MHC molecules loaded with antigenic peptides together with costimulatory signals. The coordinated delivery of both signals to T cells ensures the induction of a productive T cell response (2) (3). At least some aspects of cytokine-induced DC maturation are counteracted by antiinflammatory stimuli (4).
In the MHC class II presentation pathway, lysosomal proteases of the cathepsin (cat) family control the processing of Ag and the formation of peptide-receptive class II dimers (5). The nature of these cats is a matter of debate. Specific proteases may be dedicated to the presentation of certain Ags: asparaginyl endopeptidase is involved in the degradation of tetanus toxin by B lymphoblasts (6). While the role of this protease in human DCs remains to be established, it is reasonable to suggest that additional proteases are critical for Ag degradation. In fact, catB is viewed as an exopeptidase responsible for the degradation of peptides, proteins, toxins, and cell surface receptors that enter the cell via endo- or phagocytosis (7) (8) (9).
The digestion of the invariant chain (Ii) is a central step in class IIdependent Ag presentation, since it is a prerequisite for the formation of peptide-occupied SDS stable class II ß dimers. The stepwise proteolytic degradation of Ii in endo/lysosomal compartments generates a heterogeneous set of
3-kD fragments, termed class IIassociated Ii-derived peptides (CLIPs), which remain bound to the class II binding groove until exchanged for antigenic peptides in a histocompatibility leukocyte Ag (HLA)-DMdependent fashion (5) (10) (11). catS is the most potent catalyst of the CLIP generation in vitro and in vivo (12) (13) (14) (15). Further potential candidate enzymes are catF, catB, catD, and catL, which degrade Ii in vitro (16). catF can degrade Ii in catS-deficient murine macrophages (17), whereas catD and catB unlikely are involved in the CLIP generation in murine cells (13) (16). catL is the pivotal enzyme for Ii degradation in thymic epithelial cells and, hence, is required for positive selection of CD4+ thymocytes (18).
The expression levels of several cat family members are upregulated by IL-4 and IFN- (16) (19) (20), both of which are potent inducers of class II expression in different cell types. Stimuli that induce DC maturation might also regulate the activity of proteases relevant for the generation of exogenous Ag-derived peptides and proteases that are responsible for the generation of SDS stable class II dimers. Along these lines, it has been suggested that the regulation of cystatin C (Cy C) levels in DCs controls the activity of catS in the course of maturation (21). The effects imposed by antiinflammatory stimuli on DC function might likewise act by controlling the levels of intracellular proteolytic activity. IL-10 impairs class IIdependent Ag presentation in a cell typedependent fashion (4) (22) (23) (24) and is the prototype cytokine that inactivates DCs in vivo and in vitro (25).
Here we asked whether protease activity is dynamically regulated by physiologically relevant stimuli and, if so, which are the enzymes affected. Cytokine-mediated regulation of protease activity might help us understand how pro- and antiinflammatory stimuli balance class II assembly and Ag processing. Therefore, we examined the nature and function of cats involved in class IIdependent Ag presentation by human DCs and analyzed the effects of pro- and antiinflammatory cytokines on cat activity and T cell activation.
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Abs and Reagents.
CBz-Tyr-Ala-CN2 was provided by H. Chapman (University of California at San Francisco, San Francisco, CA) and iodinated. Anti-CD45 (MEM-28) and antiHLA-DR (MEM-12) mAbs were provided by V. Horejsi (Academy of Natural Sciences, Prague, Czech Republic). Rabbit anticat sera (anti-B, -L, -D, -S) were provided by E. Weber (University of Halle-Wittenberg, Halle, Germany). N-morpholinurea-leucine-homophenylalanine-vinylsulfone-phenyl (LHVS; provided by J.T. Palmer, Arris Pharmaceuticals, San Francisco, CA), Fmoc YACHN2 (provided by R.W. Mason, Alfred I. duPont Hospital, Wilmington, DE; reference 26), and CA074Me (Bachem Feinchemikalien AG) were dissolved at 10 mM in DMSO and stored at -20°C. Chloroquine and bafilomycin A1 were from Calbiochem.
Cell Preparation and Culture.
B cells were prepared from PBMCs by anti-CD19 (Leu12; Becton Dickinson) immunostaining and flow sorting (FACStarPLUSTM; Becton Dickinson). CD34+-derived DCs, and CD11c+ and CD11c- peripheral blood DCs were prepared as described (27) (28). Monocyte-derived (md) DCs were prepared in the presence of 1 ng/ml TGF-ß1 (R&D Systems) in serum-free conditions (LGM3 medium; CLONTECH Laboratories, Inc.; reference 29). mdDCs were stimulated with 100 ng/ml TNF- and 10 ng/ml IL-1ß (both R&D Systems; referred to as "TNF/IL-1 stimulation"). When indicated, cells were precultured with 300 U/ml IL-10 (R&D Systems) overnight before stimulation. Tetanus toxoid (TT)-specific T cell clones (TCCs) were established and characterized as described (30).
Detergent Extraction and Immunoblotting.
Cells were solubilized, lysates were submitted to 12% SDS-PAGE, and immunoblotting was performed (31). mAb MEM-28 (1:5,000), rabbit anti-actin (1:5,000; Sigma-Aldrich), or rabbit anticat sera (1:5,000 or 1:2,500) were incubated for 6 h. The binding of peroxidase-conjugated donkey antirabbit IgG or sheep antimouse IgG F(ab')2 (both 1:20,000; Amersham Pharmacia Biotech) was detected using ECLplusTM (Amersham Pharmacia Biotech).
Metabolic Labeling and Immunoprecipitation.
DCs were starved in methionine and cysteine-free medium, pulsed for 30 min with 1 mCi/ml (510 x 106 cells/ml) of InVivo CellTM labeling mix (Amersham Pharmacia Biotech), aliquoted, and chased at 37°C. Protease inhibitors were added 4 h before pulse. Cells were lysed at the indicated time points as described (31). Lysates were precleared with protein G beads (Sigma-Aldrich) and antiHLA-DR immunoprecipitation (mAb TÜ36; BD PharMingen) was performed for 3 h. Precipitated proteins were eluted for 20 min with nonreducing PAGE sample buffer containing 2% SDS. Nonboiled and boiled aliquots of each sample were analyzed by 12% SDS-PAGE.
Active-site Labeling of Cysteine Proteases.
0.51 x 106 DCs were stimulated with TNF/IL-1 in the presence or absence of protease inhibitors. Cells were washed, incubated with CBz-125I-Tyr-Ala-CN2 for 30 min at 37°C, washed again to remove free label, and lysed. 12% SDS-PAGE was performed under reducing conditions. Cellular protein content per lane was defined by the use of equal cell numbers per sample. Even loading was controlled by Coomassie blue staining of each gel.
Ag Degradation Assay.
DCs were incubated with 10 µg/ml of anti-FcRII mAbs (IV.3; Medarex) for 1 h at 4°C, washed, and exposed to 125I-labeled goat antimouse IgG (Amersham Pharmacia Biotech) for 1 h at 4°C. After extensive washes with cold PBS, aliquots of 0.5 x 106 cells were chased under various conditions. Then cells were lysed, lysates were mixed with nonreducing sample buffer, and subjected to 10% SDS-PAGE. No signals from [125I]IgG were obtained without the anti-Fc
RII incubation step. Cellular protein content per lane was controlled as described.
Gel Densitometry.
The amount of SDS stable class II ß dimers and of Ii fragments was defined as follows: intensity of the respective band regions was determined from digitalized autoradiograms using the Kodak 1D v2.02 software package (Eastman Kodak Co.). Values obtained from the ß chains of boiled precipitation aliquots were considered 100% for the calculation of the amount of the corresponding SDS stable
ß dimers or small leupeptin-induced Ii peptide (SLIP). Signal intensities from [125I]IgG were quantified as described.
Assessment of Ag Internalization.
DCs were exposed to 10 µg/ml biotinylated anti-FcRII or control mAbs (MOPC 21; Sigma-Aldrich) for 30 min at 4°C. After washing, cells were incubated with goat anti-mouse F(ab')2 (Molecular Probes) for another 30 min at 4°C to cross-link receptor-bound mAbs. Excess F(ab')2 was removed and internalization of surface-bound Ab complexes was monitored after various culture periods at 37°C as follows: DCs were harvested, chilled, and incubated with PE-labeled streptavidin (1 µg/ml SA-PE; Becton Dickinson) for 30 min at 4°C. PE fluorescence was analyzed using a FACScanTM flow cytometer (Becton Dickinson) and expressed as the specific mean fluorescence intensity (MFI;
MFI, MFI of anti-Fc
RII mAb-stained cells minus MFI of control mAb-stained cells). The ratio of the
MFI of DCs cultured at 37°C over the
MFI of DCs kept on ice multiplied by 100 gives the percentage of ligand internalization.
Acidity of Endocytic Compartments.
DCs were exposed to anti-FcRII mAbs followed by receptor cross-linking with FITC- or oregon green (OG)labeled goat antimouse F(ab')2 (Molecular Probes) at 4°C. Cells were washed and cultured at 37°C. pH-sensitive FITC and pH-insensitive OG fluorescence was measured by FACS®. The ratio of FITC over OG fluorescence was calculated for DCs cultured for the indicated time periods at 37°C. The FITC/OG ratio of cells kept on ice was set at 100%. Ratios determined from DCs cultured for various time periods were expressed as the percentage of this value. Results are given as the percentage of specific reduction of FITC fluorescence relative to the baseline value (0%; 0 h). Additionally, the pH of endocytic DC compartments was assessed directly using LysoSensorTM yellow/blue conjugated to 0.25 mg/ml 10-kD dextran (Molecular Probes; reference (32)). DCs were labeled overnight in the presence or absence of IL-10. TNF/IL-1 was added for the indicated time periods, cells were washed in PBS, and the fluorescence emission of internalized LysoSensorTM was measured within the next 10 min using an Axiovert 100 microscope (ZEISS) equipped with the AttofluorTM system (Atto Instruments; excitation: 365 ± 12 nm; emission: 515530 nm and 450490 nm). The ratio of green over blue emission of at least 10 randomly selected cells/microscopic field was calculated using the AttofluorTM ratio vision software (Atto Instruments). Standard curve for intracellular pH measurement: calibration buffer (125 mM KCl, 20 mM NaCl, 0.5 mM CaCl2, 0.5 mM MgCl2) was titrated to pH 4 or 5 with 25 mM acetic acid, pH 6 with 25 mM MES (Merck), and pH 7 with 25 mM morpholino propane sulfonic acid (Sigma-Aldrich). Cells of defined intracellular pH were generated by incubation with pH-adjusted calibration buffers supplemented with 10 µg/ml nigericin and 10 µg/ml monensin (Sigma-Aldrich). Ratios of at least 10 cells/pH grade were acquired as described above.
Assessment of Expression and Surface Stability of HLA-DR.
DCs were analyzed in parallel for surface and total cellular HLA-DR expression by FACS®. For the latter analysis, cells were subjected to Fix&PermTM (An der Grub Bioresearch) and stained with 1 µg/ml FITC-labeled mAb L243 (Becton Dickinson). The surface stability of HLA-DR complexes was analyzed with biotinylated Fab fragments of 10 µg/ml MEM-12. DCs were labeled for 30 min at 4°C, washed, and cultured for the indicated time periods at 37°C. Biotin moieties remaining at the cell surface were detected with SA-PE.
TCR Downregulation Experiments.
TCR downregulation experiments were performed as described with minor modifications (33) (34). DCs were labeled with 20 nM CFDA-SE (Molecular Probes) in PBS for 20 min at 37°C, washed, and incubated for 30 min with TT (Calbiochem) or TT peptides (TT947967; Pichem) at the indicated concentrations or medium only. After washing thoroughly DCs were chased, mixed with a TT-specific TCC (DC/T cell ratio 4:1 in RPMI 1640, 10% human AB serum; PAA Laboratories), and cocultured for 4 h. TCR internalization was stopped and DC-T cell clusters were disrupted by chilling with cold PBS and 0.5 mM EDTA. T cells were stained with PE-labeled anti-CD3 (Leu4; Becton Dickinson) or isotype control mAbs (Becton Dickinson) and analyzed by FACS®. MFI values of gated T cells were calculated as described above and transformed to absolute numbers of TCR/CD3 molecules per cell using the QuantiBRITE PETM calibration kit (Becton Dickinson). The numbers of triggered TCRs were calculated by subtracting the TCR/CD3 numbers of T cells cocultured with Ag-modified DCs from those of T cells exposed to nonAg-modified DCs.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
DCs Acquire High Levels of Mature cats during Their Differentiation from Precursors.
We used mdDCs as model DCs as large cell numbers are easily accessible at an immature stage and selected culture conditions in which mdDCs do not produce IL-10 endogenously (29) (35). This allows a comparison of the effects of pro- versus antiinflammatory cytokines on DC function. We first defined expression patterns of cats to see whether the proteases expressed in mdDCs were representative of human DCs.
Protease activity can be examined by at least two independent methods. First, the level of proteases themselves can be measured by immunochemical methods. However, the assessment of the total protease content based on immunoblotting may not yield an accurate estimate of the level of active enzyme. Therefore, the second approach is to measure the activity of the proteases using active sitedirected, mechanism-based inhibitors. Using these two types of approach, we addressed the changes in protease content and activity that accompany the development and the maturation of DCs. First, cat expression in B cells, monocytes, various types of DCs, and DC precursors was assessed by immunoblotting (Fig 1 A). None of the proteases analyzed (catB, catD, catL, and catS) was detectable as the mature form in resting B cells. The only cat clearly detected in these cells is the proform of catB, also expressed in monocytes. Low level cat expression by resting B cells could have escaped detection by immunoblotting. It is equally possible that resting B cells have to undergo activation and maturation for high level cat expression. Monocytes express pro-catB, pro-catL, pro- and mature catS, as well as pro- and mature catD. During the transition from the monocytic precursor to the immature mdDC, mature catB is expressed de novo and several cats (mature catS, mature catD, and pro-catL) are upregulated. Importantly, the cat expression profile of mdDCs is virtually identical to CD34+ stem cellderived DCs, and the cat pattern of monocytes, the mdDC precursors, is similar to other well-defined DC progenitors (28); peripheral blood CD11c+ DC (DC1) precursors and CD11c- plasmacytoid DC (DC2) precursors express the proforms of catB and catL as well as mature catS and catD. The levels of mature enzymes detected are low, probably related to the relative immaturity of DC1 and DC2. Thus, resting DCs and DC precursors differ in the expression levels of pro versus mature proteases only. Our data allow the conclusion that, as far as protease content is concerned, mdDCs (referred to as "DC" from now on) can be used as a representative DC population for our studies.
|
Do stimuli that control distinctive DC functions regulate the cat expression profile of DCs? The proinflammatory, "DC maturationinducing" cytokines TNF- and IL-1ß do not induce significant changes in the protease levels detected in DCs (Fig 1 B). Total intracellular protease content was equally insensitive to treatment with the antiinflammatory stimulus IL-10 alone. Expression of pro-catB was not significantly altered by exposure of DCs to IL-10 plus TNF/IL-1. However, stimulation of IL-10treated cells with TNF/IL-1 lowers the levels of other proenzymes (pro-catL, pro-catS) and downregulates the expression of mature catB, catS, and catD within 24 h. We next analyzed the kinetics of individual enzymatic activity levels in response to pro- and antiinflammatory stimuli.
Pro- and Antiinflammatory Cytokines Regulate Intracellular cat Activity in a Reciprocal Fashion.
catS, catB, and catL activity can be monitored in intact cells with the active sitedirected probe CBz-125I-Tyr-Ala-CN2. catB and catS were constitutively active in resting DCs (Fig 2 A, left). Stimulation of DCs with TNF/IL-1 induces a rapid (within 30 min) increase in the activity of catS and catB (Fig 2A and Fig B, left). No catL activity was observed in resting or activated DCs in most experiments (in 2/20 experiments catL activity was detected after 12 h of stimulation; data not shown). Quantitative analysis (Fig 2 A, right) demonstrates a sixfold increase of catS activity accompanied by a moderate, but significant (greater than twofold) induction of catB activity upon stimulation with TNF/IL-1. Inclusion of 5 nM LHVS completely blocked catS over the period of observation. Exposure of DCs to the broad cysteine protease inhibitor leupeptin resulted in complete loss of all detected cats (Fig 2 A, left). Although IL-10 alone does not decrease catS and catB activity in DCs (Fig 2 B, 0 h), it attenuates the TNF/IL-1mediated upregulation of catS and catB and induces a successive loss of both active enzymes in TNF/IL-1stimulated DCs (Fig 2 B). In summary, these data show that proinflammatory cytokines induce an immediate upregulation of enzymatic activity that can be suppressed by the antiinflammatory stimulus IL-10. Does such a cytokine-dependent regulation of proteolytic activity affect class II processing?
|
Cytokine-induced catS Activity Mediates Rapid and Efficient SDS Stable Class II ß Dimer Formation.
We examined the kinetics of class II maturation in TNF/IL-1stimulated and resting DCs by pulse-chase analysis. The metabolically labeled, nonstimulated cells maintained the HLA-DRlowCD86lowCD83- phenotype of immature resting DCs and responded to TNF/IL-1 stimulation equally well as nonlabeled DCs (data not shown). Immunoprecipitations were performed at the indicated time points from cell numberadjusted aliquots of metabolically labeled DCs using the HLA-DRspecific mAb TÜ36. This mAb recognizes HLA-DR-ß bound to full-length Ii (splice variants p31/33, p41, and the highly sialylated form of p41, p47), or to Ii remnants (SLIP, leupeptin-induced Ii peptide [LIP], CLIP), as well as HLA-DR-
ßpeptide complexes. Fig 3 A shows the rapid formation of SDS stable class II
ß dimers in TNF/IL-1activated DCs. After a 2-h chase, stimulated DCs already contained 36% of the total HLA-DR-ßbound radioactivity in SDS stable HLA-DR-
ß dimers (average, n = 3). This value increases to 73% after 16 h (Fig 3 B). In contrast, in resting DCs (Fig 3 E) SDS stable class II dimers appear slowly and rather inefficiently (only 36% of HLA-DR-ß incorporated radioactivity in SDS stable dimers after 16 h). Dimer formation by resting DCs is hardly affected by catS blockade (Fig 3E and Fig G) and few SLIP fragments accumulate when LHVS is added to the culture (Fig 3 F). This finding is consistent with the rather low level of catS activity of resting DCs, as detected with CBz-125I-Tyr-Ala-CN2 (Fig 2 A). LHVS-mediated inhibition of catS in activated DCs induces the accumulation of SLIP (Fig 3a and Fig C) and a pronounced, but temporary, inhibition in the generation of SDS stable class II dimers (Fig 3a and Fig B). These findings correlate well with the activation-induced upregulation of catS activity (Fig 2). In summary, the wave of MHC class II SDS stable dimer formation induced by TNF/IL-1 (Fig 3 D) depends on and is mediated by the immediate upregulation of catS activity seen in response to such treatment.
|
IL-10 Alters Class II Processing by Modulating cat Activity.
Is the observed IL-10mediated downregulation of cat activity relevant for Ii degradation and SDS stable class II ß dimer formation? TNF/IL-1stimulated DCs, either unmodified or precultured in IL-10 or LHVS-containing medium, were metabolically labeled and subjected to HLA-DR immunoprecipitation. As expected, inhibition of catS by LHVS induces accumulation of SLIP (Fig 4 A). SLIP appears in precipitates from IL-10exposed but not from control DCs (Fig 4 A). Since catS is the major enzyme that can effectively digest SLIP in TNF/IL-1stimulated DCs, it appears that IL-10 impairs catS activity such that it affects class II maturation. Indeed, exposure of DCs to IL-10 leads to a delay in SDS stable dimer formation (Fig 4 B), but has no effect on the synthesis of the class II subunits themselves (Fig 4 A). Thus, it appears that the temporary accumulation of SLIP in stimulated, IL-10treated DCs is because of the combined action of the TNF/IL-1mediated increase in class II synthesis and the attenuated catS activity in response to IL-10.
|
As IL-10 suppresses not only catS but also catB activity, we assessed the relative impact of either protease on class II maturation. For this purpose, the catB- and the catS-specific inhibitors CA074Me and LHVS were used to create catB- and/or catS-deficient cells (Fig 4 C) for pulse-chase analysis. 100 nM CA074Me did not influence or only moderately influenced catS activity during the 16-h chase period (4-h time point in Fig 4 C). In agreement with our earlier results, catS but not catB mediates rapid SDS stable dimer formation in cytokine-stimulated DCs. Our conclusion that dimers that form late during the chase period rely on catB rather than catS activity is, however, based on the assumption that CA074Me does not prevent the activation and maturation of enzymes other than catB. DCs deficient for both enzymes show reduced dimer formation during the entire time period analyzed (Fig 4 D). This temporal resolution of the individual enzyme's contributions suggests that they serve discrete functions in the class II pathway. Accordingly, LHVS, but not CA074Me, induces the accumulation of Ii remnants (Fig 2 and Fig 4, and data not shown).
IL-10 Inhibits Ag Degradation by DCs.
To further characterize the functional importance of catB in DCs, we asked whether pharmacological or cytokine-mediated modulation of catB results in impaired Ag degradation and, consequently, altered peptide display. Digestion of iodinated IgG internalized via FcRII was used to investigate Ag degradation by DCs. Equal numbers of Ag-loaded cells were chased for various time periods and fragmentation patterns of internalized IgG were analyzed. TNF/IL-1 treatment increases the capacity of DCs to degrade Ag, as judged from the accelerated disappearance of both full-length IgG and its fragments (Fig 5 A). IL-10 treatment of nonstimulated cells was without visible effect (data not shown). When IL-10treated DCs were stimulated with TNF/IL-1, their Ag degradation capacity changed considerably (Fig 5 B). Untreated and IL-10treated DCs internalized IgG with virtually identical kinetics and efficacy (Fig 5 C) excluding the possibility of prolonged Ag persistence at the cell surface. In stimulated DCs, intact Ag has a t1/2 of
1 h and degradation products are hardly discernible (Fig 5 B). The presence of IL-10 increases the t1/2 of intact Ag to >8 h and protein fragments ranging from 20 to 60 kD become prominent (Fig 5B and Fig D). Similar to the results seen in the Fc
RII targeting experiments, the degradation of IgG taken up via the mannose receptor pathway of macropinocytosis (36) was inhibited by IL-10 although internalization rates were not at all affected (data not shown). We conclude that IL-10 indeed inhibits the Ag degrading capacity of DCs.
|
IL-10 Inhibits Ag Degradation by Inhibiting catB Activity and by Modulating the pH of Endocytic DC Compartments.
Do specific cat inhibitors and IL-10 induce similar Ag fragmentation patterns? If so, a comparison between inhibitor- and IL-10treated cells could provide further clues as to the key protease(s) involved. IL-10 treatment of DCs induces the accumulation of IgG fragments in the range from 20 to 60 kD (Fig 6 A). Although 100 nM CA047Me selectively inhibited catB in our experimental setting (Fig 4 C), a single mode of interference still may not be sufficient to allow definitive conclusions about the function of this enzymatic activity (37). Thus, we decided to use three independent strategies to block catB, i.e., exposure of DCs to (a) CA047Me (38), (b) the catB/catLspecific inhibitor Fmoc YACHN2 (26), and (c) a high concentration of LHVS (0.5 µM) that eliminates catB, catL, and catS activity (12) (16) (39). Each condition produced an Ag fragmentation pattern quantitatively and qualitatively similar to IL-10exposed DCs (Fig 6 A). Thus, these fragments are attributable to IL-10mediated inhibition of catB. catS and catL are not required for Ag degradation in the presence of active catB. catS and catL become important only in the absence of active catB. This is seen from the accumulation of fragments <30 kD in catL/catB and catS/catBdouble deficient cells to an extent similar to IL-10exposed DCs. Data from cat B-/- mice show only a modest shift in the efficiency of presentation of certain antigenic determinants indicative for a minor role of this protease for Ag degradation in murine splenocytes (40). Our results with human DCs differ from this observation and underline again the importance of studying defined populations of APCs in their own sight. In summary, we conclude that catB is a major Ag-degrading protease of human DCs and, further, that catB activity is negatively regulated by IL-10.
|
Since the pH of endo/lysosomal compartments is a critical factor regulating the activity and stability of cats (16) (41), we asked whether IL-10 inhibits protease activities in DCs by elevating the pH of the endocytic pathway. DCs were labeled with mouse mAbs to FcRII followed by antimouse Abs coupled to a low pH-sensitive dye (FITC), and pH-dependent FITC quenching, which accompanies ligand internalization, was monitored (Fig 6 B). In the presence of IL-10, intracellular FITC quenching was strikingly reduced whereas the kinetics and efficacy of ligand internalization were not affected (Fig 6 B). Using quantitative ratio measurements of fluorescence emission, we further demonstrate directly that endo/lysosomal compartments of IL-10treated stimulated DCs are less acidic than those of control cells (Fig 6 C). Calculations based on the standard curve show that the average pH in endocytic compartments changes from pH 4.5 to 5.3 (data not shown).
Do drugs that raise the pH of the endo/lysosomal system reproduce the effects of IL-10 in DCs? DCs were exposed to the lysosomotropic drugs bafilomycin or chloroquine and monitored for their cat activity, their total intracellular protease content, and for their Ag degradation capacity. Active-site labeling shows that catB and catS activity are massively downregulated upon exposure of DCs to either of the pH-modulating drugs (Fig 6 D). Both compounds significantly lower the total intracellular protein levels of mature catB and catS in DCs as assayed by immunoblotting (data not shown). Importantly, DCs exposed to bafilomycin were largely incapable of degrading intact Ag taken up via FcRII and showed accumulation of a major 50-kD IgG fragment also prominent in IL-10treated and catB-deficient DCs (Fig 6 A). According to the literature, IL-6 acidifies endosomes in DCs (42). Our data suggest that IL-10, by raising endo/lysosomal pH, induces the opposite effect. Indeed, IL-6 reverses the IL-10induced impairment of Ag degradation (data not shown). Thus, we conclude that regulation of endosomal pH by IL-10 contributes to the control of proteolytic activity.
IL-10 Prevents Long-Term Delivery of a TCR Signal.
TNF/IL-1induced accumulation of HLA-DR at the cell surface is clearly impaired by IL-10 as determined by FACS® (Fig 7 A). Likewise, leupeptin treatment results in reduced class II surface expression upon exposure to TNF/IL-1 (Fig 7 A). In contrast, neither IL-10 nor leupeptin clearly affects the surface expression of HLA-DR in resting DCs (Fig 7 A, time point 0), the TNF/IL-1induced upregulation of total cellular HLA-DR (Fig 7 B), and the stimulation-induced downregulation of macropinocytotic Ag uptake (data not shown). Reduced HLA-DR surface expression seen in IL-10treated DCs most likely involves an export defect since internalization of class II from the cell surface was not enhanced by IL-10 or leupeptin (Fig 7 C, and data not shown). These results strengthen the interpretation that IL-10 affects class II trafficking by regulating lysosomal protease function and not simply by preventing TNF/IL-1induced activation of DCs.
|
To analyze the impact of IL-10 on the surface display of class IIbound peptides, we exploited internalization of newly engaged TCRs as a measure of specific class IIpeptide display (43). Activated DCs were pulsed with TT or TT peptides and analyzed for their capacity to trigger TCRs of TT-specific TCCs. The kinetics of peptide-induced TCR triggering by IL-10treated DCs is comparable to untreated cells (Fig 7 D), yet the extent to which downregulation of the TCR occurs is markedly less. The lower level of TCR triggering by IL-10treated DCs must correspond to their reduced display of HLA-DR loaded with TT peptides at the cell surface. As expected, TCR downregulation by peptide-pulsed DCs occurs instantaneously and decays during the chase. In contrast, TCR triggering by TT-pulsed DCs requires >1 h of processing of TT, but thereafter increases constantly over hours to days (Fig 7 D, and data not shown). The level and kinetics of processing-dependent presentation of TT are significantly altered by IL-10 exposure of DCs (Fig 7 E). Until 7 h after the pulse, similar numbers of TCRs are triggered by IL-10treated and control DCs. Thereafter, the TCR-triggering capability of IL-10exposed DCs drops. No additive defect in peptide presentation was observed when DCs were exposed to IL-10 and catB inhibitors simultaneously (data not shown), supporting the role of IL-10 in regulation of catB activity.
To quantify the IL-10 effect on class IIpeptide display, DCs were pulsed with various concentrations of TT or TT peptides and the numbers of TCRs triggered by these cells were measured. We observed a strictly linear correlation between the numbers of triggered TCRs and the logarithm of the concentrations of intact protein Ag as well as peptide used during the pulse (Fig 8 A). The two regression curves are parallel, indicating that synthetic peptides and the peptides generated from TT protein by DCs are incorporated into class II complexes of comparable TCR triggering capacity. A linear correlation exists between the logarithm of the absolute number of class IIpeptide complexes displayed and the number of TCRs triggered (33). Therefore, we conclude that a linear correlation exists also between the Ag concentration encountered by the DC and the absolute number of MHC class IIpeptide complexes transported to the cell surface. Consequently, when the measured numbers of triggered TCRs (ordinate; Fig 8 A) are projected onto the TT regression curve, the value obtained on the abscissa is a direct measure of the number of MHC class IIpeptide complexes displayed by the DC.
|
IL-10exposed and control DCs were pulsed with 5 or 50 nM TT and assayed for their TCR triggering capacity after various chase periods. IL-10 strikingly reduces the t1/2, but less so the amplitude, of the signal delivered by DCs to the TCR (Fig 8 B). Importantly, the inhibitory effect of IL-10 on class II-peptide display was equally pronounced at 5 and 50 nM TT. The peptide-bound class II ß complexes formed initially disappear from the cell surface with a t1/2 of 1215 h (Fig 8 B) and with kinetics strikingly similar to those of class II molecules loaded with synthetic peptide (Fig 7 D, and data not shown). In summary, IL-10 prevents the continuous formation of peptideclass II complexes and/or their export from the endo/lysosomal system and, as a result, directly affects T cell activation.
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
For DCs to evoke a primary T cell response, processing of internalized Ag and proper maturation of MHC class II complexes are essential. We have examined the nature and function of cats capable of mediating these events in mdDCs as examples of professional APCs. This choice is validated by our observation that the cat expression pattern of mdDCs is representative of other types of DCs. We show that Ag processing and class II maturation are controlled by at least two proteases with discrete functions, catS and catB. DCs almost instantaneously upregulate the activity of both enzymes in response to proinflammatory cytokines, an effect counteracted by the antiinflammatory cytokine IL-10. Based on the use of specific inhibitors we conclude that catS is one of the major enzymes that generates SDS stable class II dimers in human DCs. The catS-dependent pathway of class II dimer formation operates efficiently when DCs encounter proinflammatory cytokines and is inhibited by IL-10. Class II SDS stable dimer formation in DCs is sensitive to catS inhibition by LHVS, but only early in the course of biosynthesis. Furthermore LHVS-induced accumulation of SLIP and catS-dependent dimer formation show strikingly similar kinetics.
In the absence of proinflammatory stimuli, DCs display baseline catS activity and do not accumulate class IISLIP complexes. This situation differs from that described for immature murine bone marrowderived DCs, which accumulate SLIP and are therefore thought to be devoid of catS activity (21). In this regard, our observation underscores the differences between human and murine APCs. Active catS mediates SLIP degradation in resting human DCs, as seen from the immediate accumulation of SLIP induced by LHVS treatment. Nonetheless LHVS-exposed, cytokine-activated DCs still show SLIP degradation and SDS stable dimer formation, but at a reduced rate, suggesting the involvement of other unidentified proteases. catF, a SLIP degrading enzyme in mouse macrophages (17), is an obvious candidate for this phenomenon. LHVS at 20 nM, a concentration shown to interfere with catF activity (17), was unable to abolish SLIP degradation in our experimental system (data not shown). The lack of cell-permeable, catF-specific probes renders functional studies on a possible contribution of catF difficult at the moment. Our data clearly show that catS is used preferentially when DCs are activated. Then its activity and importance for SDS stable dimer formation clearly exceeds that of the other presumably less efficient enzymes.
Proinflammatory stimuli evoke rapid formation of peptide-loaded class II dimers by upregulating cat activity, whereas antiinflammatory stimuli like IL-10 counteract this. The fast increase (within 30 min) in protease activity in response to TNF/IL-1 rather excludes transcriptional regulation as the underlying mechanism. Although still to be proven experimentally, it is likely that relocalization of (pro)enzymes into compartments with pH levels that favor enzymatic activity occurs in a cell activationdependent fashion. According to the literature (21), Cy C is involved in the inhibition of cat activity in murine DCs. Thus, we investigated whether cytokines that modulate cat activity also regulate the expression or the subcellular distribution of this endogenous cat inhibitor. However, neither immunoblotting nor confocal laser scanning microscopy revealed significant changes in Cy C levels or localization in response to any of the applied cytokines (data not shown). In summary, our data argue against the possibility that Cy C is involved in cytokine-mediated cat regulation in human DCs.
The decrease in cat activity by IL-10 is physiologically relevant, as demonstrated by the reduced ability of IL-10treated DCs to activate T cells. catB's major enzymatic targets are Ags that enter DCs via macropinocytosis (mannose receptor dependent) or via coated pits and vesicles (FcRII mediated). IL-10 inhibits the degradation of both full-length protein Ags and Ag fragments. Pharmacologic inhibition of catB, but not of catS or catL activity, similarly inhibits Ag degradation. Some Ag breakdown products appear early after Ag loading in IL-10treated and pharmacologically catB-depleted DCs. Enzymes that may attack complex protein Ag include asparaginyl endopeptidase, a protease implicated in TT cleavage (6) (44). Our observation that full protein Ag persists while the Ag fragments formed initially decay in IL-10treated DCs shows that the activity of these proteases is attenuated by IL-10.
The alteration of the intracompartmental pH may contribute to the inhibition of cat activity by IL-10. IL-10 can influence the pH of Ag-loading compartments, as demonstrated by increased acidification of mycobacterial phagosomes in macrophages from IL-10 knockout mice and, vice versa, decreased acidification upon exposure of susceptible cells to this cytokine (45). We show that internalized Ags experience a less acidic milieu in DCs exposed to IL-10. Pharmacological inhibition of acidification mimics the IL-10induced defect in Ag degradation. Whereas the expression of proteases that are more stable at a pH close to neutral is hardly affected, IL-10 treatment downregulates the mature form of those proteases that require acidic pH for their stability (catD, catB; reference 41). Thus, inhibition of enzymatic activities induced by IL-10 most likely includes pH-regulated maturation and activation, pH-dependent autocatalytic degradation, and, for some proteases, the release into extracellular space (46). IL-10 could additionally affect cellular functions not yet addressed, i.e., the trafficking of Ags or proteases towards class II loading compartments. Moreover, it is expected that the functional program activated by exposure of DCs to IL-10 is highly complex. Array-based transcriptional profiling may be helpful in defining this program, and in turn, may allow a more directed cell biological analysis of IL-10's inhibitory effects on Ag presentation.
We used the TCR triggering assays for a semiquantitative estimate of peptide display by cytokine-modified DCs. Titration and kinetics revealed that pro and antiinflammatory cytokines regulate the levels of surface class II peptide display by DCs in a differential manner. Remarkably, a simple mathematical term describes the relationship between the concentration of Ag/peptide pulsed onto the DC and the number of TCRs engaged during a cognate DCT cell interaction. The logarithm of the Ag and peptide concentration and the number of triggered TCRs correlate in linear fashion. The number of class IIpeptide complexes on the APC surface and the number of engaged TCRs are also correlated in semilogarithmic fashion (43). Therefore DCs convert extracellular Ag into surface-disposed class II peptide complexes with constant molar efficacy. The fact that serial triggering of TCRs is most efficient when the APC expresses one or only few class II complexes containing the relevant peptide renders the class II display measurement extremely sensitive. The linear regression calculated for the display of peptides derived from TT intersects the abscissa at an Ag concentration of <10-10 M. Thus, on average, each DC displays one TT peptide at an Ag concentration of 10-10 M. DCs internalize extracellular fluid equal to their own volume (
2.5 x 10-13 l) in
1 h (36). Based on the assumption that the major internalization mechanism for TT by DCs is fluid-phase uptake (47), we calculate that a DC pulsed with 10-10 M TT (i.e., 6.023 x 1013 molecules/liter) for 30 min internalizes 1.3 x 10-13 liter of the solute, equivalent to
8 TT molecules. The internalization of this small number of intact Ag molecules suffices to trigger several hundred Ag-specific TCRs. We observed that TNF/IL-1stimulated DCs express approximately twice the amount of TT peptidebearing class II complexes when compared with unstimulated controls after a short Ag pulse (data not shown). The ability of unstimulated DCs to display TT peptide in the context of class II was described previously (1). In contrast, others observed that stimulated but not unstimulated murine DCs can present a peptide derived from a hen egg lysozyme (48) (49). In summary, these findings support previous suggestions that human DCs and murine bone marrowderived DCs differ in terms of their Ag processing and presentation machinery (16) (50). IL-10 causes a dramatic change in peptideclass II display on the surface of DCs. Whereas peptideclass II display is only partially reduced during the first hours after the Ag pulse, long-term display of the complexes is essentially aborted in IL-10exposed cells. The decay of peptide presentation by protein Ag-pulsed, IL-10treated DCs equals peptide-pulsed DCs. The Ag presentation defect imposed by IL-10 therefore results from inhibition of formation or export, and not destabilization, of peptideclass II complexes. Thus, we, attribute limited peptide availability during the late phase of Ag presentation to IL-10mediated protease inhibition.
Immunologically naive T cells require TCR stimulation at suprathreshold intensity for >30 h before they become committed to proliferation and cytokine production (43) (51). Our findings suggest that the suppressive action of IL-10 on T cell activation may result in premature termination of TCR signals. Ag-specific tolerization of T cells by IL-10 has been attributed mainly to suppression of costimulation. When costimulation is limited, as found in connection with exposure to IL-10, the magnitude and duration of signals via the TCR decide whether Ag-specific T cell anergy or activation occurs (52). Thus, naive T cells that receive a TCR signal at subthreshold intensity or duration too short to induce their functional commitment may become anergic. If this interpretation of the effects of IL-10 were correct, then indeed manipulating protease activities could be useful to paralyze pathogenic T cells.
![]() |
Footnotes |
---|
E. Fiebiger and P. Meraner contributed equally to this work.
1 Abbreviations used in this paper: cat, cathepsin; CLIP, class IIassociated Ii-derived peptide; Cy C, cystatin C; DC, dendritic cell; HLA, histocompatibility leukocyte antigen; Ii, invariant chain; LHVS, N-morpholinurea-leucine-homophenylalanine-vinylsulfone-phenyl; LIP, leupeptin-induced Ii peptide; md, monocyte-derived; MFI, mean fluorescence intensity; OG, oregon green; SLIP, small leupeptin-induced Ii peptide; TCC, T cell clone; TT, tetanus toxoid.
![]() |
Acknowledgements |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
B. Reininger is gratefully acknowledged for technical help.
This work was supported by the Interdisciplinary Cooperation Project, a program of the Austrian Ministry for Science and a grant from Novartis Ltd., Basel, Switzerland. E. Fiebiger is supported by an Erwin-Schrödinger Fellowship from the Austrian Science Foundation.
Submitted: 25 August 2000
Revised: 16 February 2001
Accepted: 26 February 2001
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|